SCLX dividend history

PALO ALTO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today confirmed the previously announced payment date of June 15, 2026 (the "Payment Date") for the dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible holders of Scilex securities (collectively, the "Participating Holders") that held such securities as of the r

PALO ALTO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the "Board") has set June 15, 2026 as the payment date (the "Payment Date") for the previously announced dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible holders of Scilex securities (collectively, the "Participati

PALO ALTO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the "Board") approved a dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible equityholders of Scilex (collectively, the "Participating Holders"). The record date for the dividend is June 1, 2026 (the "Record Date"). Th

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the "Board") fixed May 26, 2026 (the "Payment Date") as the date on which the previously announced dividend (the "Dividend") of Dream Bowl Meme Coin I tokens held by the Company (the "Dream Bowl Tokens") will be paid to its record stockholders and certain other eligible equityholders of Scilex (collectively,

PALO ALTO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors (the "Scilex Board") approved a dividend of Dream Bowl I Meme Coin Tokens held by the Company (the "Dream Bowl Tokens") to its stockholders and certain other eligible equityholders of Scilex (collectively, the "Participating Holders"). The record date for the Dividend is April 30, 2026 (the "Record Date").

PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- via IBN-- Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, and digital engagement technologies, today announced that its board of directors (the "Datavault Board") has set Dec. 24, 2025, as the distribution date for the Dream Bowl 2026 Meme Coin token (the "Meme Coin") to all eligible record equityholders of Datavault AI.  Dec. 24, 2025, will also be the distribution date for Datavault AI's voluntary distribution of Meme Coins to record holders of common stock of Scilex Holding Company (NASDAQ:SCLX), which is being made as a token of Datavault AI's appreciation for Scilex's relat

PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT) of Dream Bowl 2026 Meme Coins to record holders of Scilex common stock, given that such distribution is being made by Datavault AI as a token of its appreciation for Scilex's relationship with Datavault AI as a stockholder of Datavault A

PHILADELPHIA, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset tokenization technologies, announced today that, in connection with its previously announced distribution of Dream Bowl 2026 Meme Coins to eligible record equity holders of Datavault AI, Nasdaq has informed the Company that it is not expecting to quote an ex-dividend date for such distribution and therefore eligible record equity holders of Datavault AI must be holders as of the record date of November 25, 2025 in order to receive the distribution.  With respect to Datavault AI's volunta

PALO ALTO, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the Board of Directors of Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT) has approved the distribution of a Dream Bowl 2026 Meme Coin to all [eligible] Scilex and Datavault AI stockholders of record and set a record date of November 25, 2025 for determining stockholders entitled to receive the Dream Bowl 2026 Meme Coin from Datav

PHILADELPHIA , Nov. 11, 2025 (GLOBE NEWSWIRE) -- via IBN -- Datavault AI Inc. (NASDAQ:DVLT), a leader in data monetization, credentialing, and digital engagement technologies, today announced that the Board of Directors has approved the distribution of the Dream Bowl Draft meme coins to all eligible record holders of Scilex Holding Company (NASDAQ:SCLX) and eligible Datavault AI equity holders with a set record date of Nov. 25, 2025. The ex-dividend date to acquire DVLT and SCLX common shares is Nov. 24, 2025.  Datavault AI and Scilex shareholders as of the record date of Nov. 25, 2025 ("Record Date") will be entitled to receive one meme coin for each common share held. Short sellers of D

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it is sponsoring the Dream Bowl 2026 and set a record date of November 14, 2025 for its shareholders to receive Dream Bowl 2026 Meme Coin, which will be distributed by DataVault AI. Scilex's shareholders as of the record date of November 14, 2025 will receive one meme coin for each common share held. This digital collectible is in

PALO ALTO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors (the "Board") has approved a deferral of the previously announced record date of May 2, 2025 for the Company's previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be such later date to b

PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of April 11, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be May 2, 2025 (the "New Record Date"). Subject

PALO ALTO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of January 28, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to April 14, 2025. PALO ALTO, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain manag

More patients treated with ZTlido® saw either a decrease or discontinuation of opioid use compared with those treated with the 5% patch (51.9% vs. 45.5%).Of all study patients reporting a decrease in opioid use, significantly more in the ZTlido® group experienced a 20% or greater reduction in opioid use, compared with those treated with 5% lidocaine patch (21.3% vs. 13.4%; P=0.0008).Patients on ZTlido® had a non-significant change in their baseline opioid use (+3.1%; P=0.146), while those using the 5% patch experienced a significant increase in opioid use from baseline (+42.9%; P<0.001). PALO ALTO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or

PALO ALTO, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of November 7, 2024 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record

As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator

Scilex management is determined to enhance its stockholders' value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock.Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex. Such record date may be changed by Scilex's board of directors for any reason at any time prior to the actual payment of such dividend of Scilex preferred stock. No payment date has been set for the payment of such dividend and such payment is conditioned upon the Scilex board of director

Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with

Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to January 31, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to January 31, 2025. PALO ALTO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management p

Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dexam

Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion.  The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction. The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dex

Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA) ("SPAC") announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur of up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected cash on hand at closing of up to $40 million depending on the number of SPAC shares that are redeemed prior to the completion of the business combination.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for th

PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and highly respected distributor with over 10 years of sales excellence, Endeavor Distribution LLC. ("Endeavor"). Endeavor has logistics expertise to sell and distribute our currently marketed non-opi

Scilex management is determined to enhance its stockholders' value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock.Of the approximately 181 million shares of Scilex common stock currently issued and outstanding: (a) 76 million were distributed by Sorrento Therapeutics, Inc. (OTC:SRNEQ, "Sorrento"))) as dividend shares in January 2023 (the "Dividend Shares") and are restricted from trading until the earlier of (i) September 30, 2024 per court order or (ii) the date on which Sorrento and its Official Committee of Unsecured Creditors agree in writing or on the record in Sorrento's chapter 11 cases certain

PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Bankruptcy Court for the Southern District of Texas (the "Court") has extended the expiration of the restrictions on transfer of the shares of common stock of Scilex that were previously distributed by Sorrento Therapeutics, Inc. (OTC:SRNEQ, "Sorrento"))), Scilex's former controlling stockholder, to Sorrento's stockholders as a dividend on January 19, 2023 (the "Dividend Stock"). Such l

PALO ALTO, Calif., March 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the Official Committee of Unsecured Creditors (the "Creditors' Committee") of Sorrento Therapeutics, Inc. (OTC:SRNEQ, "Sorrento"))) has filed a motion (the "Motion") with the U.S. Bankruptcy Court for the Southern District of Texas (the "Court") seeking to further extend the restrictions on transfer on the shares of common stock of Scilex that were previously distributed by Sorrento to its stock

PALO ALTO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today filed an emergency motion (the "Motion") for entry of an order compelling the production of books and records from certain brokers, dealers, banks and other nominees pursuant to Rule 2004 of the federal rules of bankruptcy procedure in the U.S. Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court").   Attached to this press release is the court motion filed by Scilex on Octobe

PALO ALTO, Calif., Oct. 07, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, retains Warshaw Burstein, LLP and Christian Attar Law to investigate potential naked short selling activities, short positions, lending program activities and constitute market manipulation of its restricted shares of common stock that were part of the previously announced dividend of Scilex common stock (the "Restricted Dividend Shares") then-held by Sorrento Therapeutics, Inc. (OTC:SRNEQ, "Sorrento")))

PALO ALTO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides notice to all record holders and beneficial owners of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. (OTC:SRNEQ, "Sorrento"))) to Sorrento equity holders of record as of January 9, 2023. NOTICE TO ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF RESTRICTED SHARES OF SCILEX HOLDING COMPAN

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC:SRNEQ, ", Sorrento", ))), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, it has posted a "Frequently Asked Questions" (FAQ) document in response to a number of requests from parties who hold short interests in restricted stock (the "Dividend Short Holders") of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))) regarding its previously announced elective offering of restricted stock of Scilex (the "Offering"). The FAQ document will be posted

PALO ALTO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex"))) announced that its majority stockholder, Sorrento Therapeutics, Inc. (OTC:SRNEQ, "Sorrento"))) has issued a notice that Sorrento's bankruptcy court has extended the expiration of the restrictions on transfer on the shares of common stock of Scilex that were distributed by Sorrento to its stockholders as a dividend on January 19, 2023 (the "Distributed Stock"). Sorrento Therapeutics, Inc. (OTC:SRNEQ, ", Sorrento", ))), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in c

SAN DIEGO, April 4, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC:SRNEQ, ", Sorrento", ))), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas entered an order requiring the top 25 brokers, dealers, banks, and other nominees that act as agents for Sorrento shareholders (the "Brokerages") to provide Sorrento with information related to the common stock of Scilex Holding Company (NASDAQ:SCLX, ", Scilex", ))), in connection with Sorrento's chapter 11 case that was filed on February 13, 2023.  As previously disclose

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an update to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the "Dividend Stock"). The update to the FAQs provides notice regarding the no lien code added on Scilex (NASDAQ:SCLX) common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed therein that a

PALO ALTO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a supplement to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation's removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento's stockholders and